Systems biology aims to provide a holistic and in many cases dynamic picture of biological function and malfunction, in case of disease. Technology developments in the generation of genome-wide datasets and massive improvements in computer power now allow to obtain new insights into complex biological networks and to copy nature by computing these interactions and their kinetics and by generating in silico models of cells, tissues and organs. The expectations are high that systems biology will pave the way to the identification of novel disease genes, to the selection of successful drug candidates-that do not fail in clinical studies due to toxicity or lack of human efficacy-and finally to a more successful discovery of novel therapeutics. However, further research is necessary to fully unleash the potential of systems biology. Within this review we aim to highlight the most important and promising top-down and bottom-up systems biology applications in drug discovery.
Biological functionality-like the secretion of insulin from the pancreatic beta cell to control blood glucose or the contraction of cardiomyocytes to pace the rhythm of the heart beat-emerges from interactions among several hundred genes and proteins within the cellular environment. In order to understand living cells, understanding these networks, identifying the most important nodes and their connections, appears to be a pre-requisite. 1 From a reductionist view to a systems view. In the last decades, drug discovery has been dominated by reductionism aiming to identify drugs that activate or inhibit specific molecular (disease) targets. However, biology is complex and it is increasingly clear that a discrete biological function-or malfunction in case of a disease-can rarely be attributed to an individual protein or gene. It also has become evident that recombinant cell lines over-expressing the single disease target that are used in screening approaches are often insufficient surrogates for the biology of primary cells or tissue. As a consequence drug molecules propagated by this simplistic view either often showed unforeseen toxicity or lack of efficacy when tested in humans in clinical trials. 2 Nowadays, disease is not seen any longer as a failure of a single gene or target, but is viewed as a consequence of disease-perturbed networks. The analysis of transcriptomics or proteomics data of individual patient tissues can provide insights into the 'signature' of the disease phenotype. The objective of a successful drug treatment would then be the reversal of the disease signature to normal. Systems biology approaches attempt to provide a more holistic and in many cases dynamic picture of biological processes. It is all about understanding biology in a context to address the right targets and the right biological mechanism by a pharmacological treatment. Technology developments in the area of, for example, next generation sequencing (NGS), transcriptomics, metabolomics and (phospho)proteomics enable parallel and high throughput characterization of biological systems. The available massive improvements in computer power allow the analysis of these genome-wide data sets to derive complex network views of biological systems and to infer the logic behind a biological function or malfunction. The computational improvements also allow copying nature by computing these interactions and their kinetics and by generating in silico models of cells, tissues and organs.
Top-down versus bottom-up system biology approaches. As outlined in Figure 1 scientists classify systems biology approaches into 'top down' and 'bottom-up' methods.
Top-down systems biology approaches attempt to identify the networks and the logic behind a biological function by the analysis of genome-wide data sets. In other words, these approaches start with a comprehensive set of data generated by one or more of the 'omics' technologies and aim to identify networks and components that are participating in the generation of a phenotype or a disease-often even without the necessity of prior knowledge. Scientists often refer to these as 'top-down' systems biology approaches. In this class belong gene-set enrichment analysis, pathway mapping, disease classification, reverse causal reasoning and network inference approaches. From the perspective of drug discovery, the top-down systems biology methods aim at a deeper understanding of the causes of a disease, to stratify patients and to identify the right molecular targets.
Bottom-up systems biology approaches try to copy nature by generating computational models of cells, tissues and organs. Here, individual components are assembled into a network with the goal to simulate the dynamic properties of the resulting system. For several biological processes these so-called molecular-mechanistic models are available, which capture and simulate cellular signalling processes (e.g., virtual heart). 3 Only recently a whole-cell computational model of the life cycle of the human pathogen Mycoplasma genitalium that includes all of its molecular components and their interactions has been published. 4 The main methods to turn these static signalling networks into computable models able to simulate the dynamics of a biological systems are ODE-based 5 or Boolean-logic based modelling. 6 Other models do not provide the molecular mechanistic detail but are more phenomenological in nature and capture the fluxes of the 'reaction' partners in the system (e.g., glucose insulin homeostasis). The objective of these modelling approaches is to shed some light into signalling processes, to identify and/or validate drug targets using a holistic and dynamic approach, to provide the key optimization parameters for a chemical optimization program and finally to predict the effect of a drug treatment in virtual patients. This 'digest' will highlight prominent examples of how systems biology can foster the understanding of cellular systems and human physiology, how it can provide insights into the logic of a biological function and/or disease and how these insights can be applied to the discovery of novel targets and drugs. The next section will provide examples on top-down systems biology approaches, whereas in the last section case studies on bottom-up systems biology approaches will be given.
One very simplistic answer to the question 'What is systems biology?' is 'making sense of the omics data'. Although this is a very simplified view it definitely describes the main objective of top-down systems biology approaches. Over the past years, due to the low cost of microarray datasets, probably millions of samples have been characterized for their basal gene expression profile and for changes in the gene regulation imposed by perturbations like diseases or drugs. Other 'omics' technologies are advancing and profiling data beyond gene expression becomes more and more available. Modern mass-spectrometry approaches allow identification and quantification of several thousands of proteins in one sample. 7 On the other hand typical metabolomics profiles now are able to resolve up to 500 metabolites by LC or GC coupled to MS/MS providing deep and informative insights. By performing global metabolite profiling, also known as untargeted metabolomics, new discoveries linking cellular pathways to biological mechanism are being revealed and are shaping our understanding of cell biology, physiology and medicine. 8 And last but not least the individual genomes-the digital source code of life-are more and more accessible as next generation sequencing technologies have delivered on their promise of sequencing DNA at unprecedented speed.
9 A significant number of recent studies wink at the idea that every biological state can be described by its specific gene expression signature: a well defined set of genes together with a pattern of expression that is exclusively linked to it. In this scenario microarray technology can be deemed as the natural language through which these 'biological-state-summaries' can be generated. Different disease-perturbed states are characterized by an expression signature that can then translate into the same disease phenotype (e.g., diabetes). This indicates that the one phenotype can have different causes. It is thought that the expression 'fingerprint' still holds more information than the clinical disease phenotype itself, as it allows to identify the activity of crucial biological pathways and to correlate these measurements with clinico-pathological features. In other words, it can hold the information for understanding the disease mechanisms and for stratification of patients.
Genome-wide data sets covering genotyping, transcriptomics, (phospho) proteomics and/or metabolomics provide rich sources of information. Systems biology not only looks into these data sets at the individual gene level to identify, for example, genes that are up or down-regulated under a certain condition, but tries to have a holistic view of this data to understand the mechanism(s) of a disease phenotype, to pinpoint disease genes, to support patient stratification and to propose drugs for re-positioning. This is achieved by the following approaches (see Fig. 2 
):
Gene-set enrichment analysis and/or mapping of differentially regulated genes on pathway maps can identify those gene sets or pathways that are significantly perturbed by, for example, a disease or drug treatment. This provides an overview of highlevel processes changing upon perturbation of the system.
10,11
Classification of diseases for patient stratification can be based on gene expression profiles and can be performed directly on the primary 'omics' data 12 or based on the strength of so-called signalling signatures.
13
Reverse causal reasoning (RCR) approaches attempt to identify the causal drivers of a disease and to understand the 'logic' behind the observed changes in a gene expression profile. [14] [15] [16] In order to generate new insights into the cellular wiring network inference approaches can be used. 17, 18 For example, novel connections can be identified by using microarray datasets and capturing the degree by which each pair of genes is co-expressed (that is, assigning each pair of genes a correlation coefficient). These gene co-expression networks can be used to complement the preexisting views on metabolic or signalling pathways. Sensitive nodes within these networks can then qualify as disease targets.
In the following we have selected several case studies to illustrate applications in these areas.
Gene-set enrichment analysis and pathway mapping. In systems biology, gene-set enrichment (GSE) analysis represents one of the most popular forms to analyze microarray and other high-throughput data. 10 By correlating ranked lists of regulated genes from a transcriptomics study with pre-defined categories of genes (e.g., pathways, biological processes) those pathways and biological processes can be identified that are most significantly changed in the sample studied (e.g., diseased vs healthy). Focusing on sets of genes rather than on individual genes has several benefits. From a statistical point of view the analysis of groups instead of individual genes is advantageous as this typically increases power and reduces the dimensionality of the underlying statistical problem. 
Bottom-Up Approaches
Top-Down Approaches Figure 1 . Systems biology approaches can be roughly divided into two categories. Bottom-up methods start from an often detailed knowledge about individual components and assemble these into larger units (e.g., a pathway) in order to simulate the behavior of this assembly. Top-down approaches start from data sets that represent huge parts of a biological system (e.g., transcriptomics data, interactome data) and try to identify those subnetworks, pathways or components that are most responsible for the systems behaviour (e.g., a phenotype).
Mostly, gene-set enrichment analysis is combined with pathway mapping, which means that the lists of regulated genes are projected onto pathway maps for those pathways that have been identified by a GSE analysis. Biological pathways have become the most popular form of representing biochemical information for hypothesis generation and validation. These maps store wide knowledge of complex molecular interactions and regulations occurring in the living organism in a simple and obvious way, often using intuitive graphical notation. Two major types of biological pathways can be distinguished. Metabolic pathways incorporate complex networks of protein-based interactions and modifications, while signal transduction and transcriptional regulatory pathways are usually considered to provide information on mechanisms of transcription. 19 Publicly available pathway databases have been recently reviewed by Bauer-Mehren et al. 20 Gene-set enrichment analysis combined with pathway mapping can not only help to pinpoint specific disease-relevant pathways, but also to discover novel disease targets or to generate hypothesis for drug repurposing. At Sanofi we have, for example, identified the mTOR pathway by mapping of differentially regulated genes in old versus young patients from muscle biopsies onto a database of networks and pathways (see Fig. 3 ). This led to the hypothesis that compounds inhibiting mTOR might be used for the treatment of sarcopenia. 21 The study suggested the repositioning of rapamycin, an immunosuppressant drug used to prevent rejection in organ transplantation. This hypothesis is currently being tested in a clinical trial that is exploring the use of rapamycin for this indication.
Classification of diseases and stratification of patients. Even a population of patients that appears to be phenotypically similar can exhibit distinct molecular disease profiles. For example, in a disease like atherosclerosis, there are multiple elements that may contribute. A similar clinical diagnosis, therefore, may be the integrated result of multiple molecular disease-driving mechanisms. Thus, the patient population in a clinical trial for a targeted therapy often represents multiple disease data subsets. As each can be driven by different molecular mechanisms, only a subset will respond to a very specific, molecularly-focussed treatment. 13 There are several examples of how biomarkers are used to identify the likely-to-respond subjects, best exemplified in oncology. Biomarkers can originate from immunohistochemical analysis (immunohistochemical detection of the estrogen receptor is used to predict the efficacy of tamoxifen in breast cancer), genotyping of the tumor sample (e.g., k-ras mutations predict resistance to anti-EGFR therapy in colon cancer) or detection of gene amplification (HER2 gene amplification is a positive indication for trastuzumab, Herceptin, treatment in breast cancer). Selecting the patient pool most likely to respond has proven beneficial for obtaining regulatory approval of effective drugs.
In a landmark paper Golub et al. presented a generic approach to cancer classification based on gene expression monitoring by DNA microarrays. 12 A classification procedure automatically discovered the distinction between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The class predictor was able to determine the class of new leukemia cases (see Fig. 4 ).
The results demonstrate the feasibility of cancer classification based solely on gene expression monitoring and suggest a general strategy for discovering and predicting cancer classes for other types of cancer, independent of previous biological knowledge. Following the idea to use gene expression monitoring for disease classification and patient stratification Laifenfeld et al. have extended this approach to develop predictive biomarkers that identify likely responders for a targeted therapeutic based upon mechanistic inferences from patient data. 13 The strategy relies upon the hypothesis that patient groups that exhibit either high levels or low levels of a gene expression signature ('signal strength')-linked to a biological perturbation, for example, the activation of the therapeutic target-will more likely respond to treatment with that targeted therapeutic. The substrate for the strategy is a knowledge base that has stored gene expression signatures for over 2000 biological perturbations from peer-reviewed publications. Each of these mechanisms can represent a potential driver of disease. Patient stratification by signal strength allows identification of those mechanisms that are most strongly or weakly activated in different subsets of heterogeneous patients and can be used in this way to identify subset most likely to respond to a molecular-targeted treatment. In a case study Laifenfeld et al. presented a classifier to predict response to a TNF targeted therapy infliximab for ulcerative colitis and verified it against a test set of patients where clinical outcomes are unknown. 13 The classifier, a 256-gene signature is reflecting the strength of TNF signalling coded by the individual levels of TNF pathway activation (see Fig. 5 ). The figure reflects that patients with lower levels of TNF pathway activation are more likely to respond to infliximab. Causal reasoning. Similar to the approach applied by Laifenfeld et al. 13 causal reasoning algorithms attempt to predict causal drivers of diseases or drug action on the molecular level. In order to provide a detailed molecular hypothesis to explain the measured Figure 2 . Top-down systems biology approaches: analysis of genome-wide datasets supports understanding of disease mechanisms, stratification of patients, discovery of novel drugs by repurposing, and identification of novel drug targets.
transcriptional changes in high fat habituated rats treated with a potent and selective diacylglycerol acyltransferase 1 (DGAT1) inhibitor Enayetalla et al. applied a causal reasoning engine (CRE). 14 The CRE utilizes the microarray transcriptomic data from rats treated with a DGAT1 inhibitor and causal statements derived from the biomedical literature to infer upstream molecular events driving these transcriptional changes. The inferred upstream events (also called hypotheses) have been aggregated into biological models using a set of analytical tools that allow for evaluation and integration of the hypotheses in context of their supporting evidence.
Mapping of drug and disease signatures. As mentioned above following the systems biology paradigm a complex disease is not seen as a failure of a single gene or target, but is viewed as a consequence of disease-perturbed networks characterized by a specific disease 'signature'. The objective of a successful drug treatment would then be the reversal of the disease signature to normal. By making use of novel non-parametric genome-wide metrics it has been possible to 'connect' drugs, genes and diseases by simply comparing the corresponding gene-expression signatures. As a consequence, several approaches have been proposed to exploit the massive amount of publicly available gene-expression data for computational 'drug re-purposing' by using a 'guilt-by-association' approach (i.e., if two drugs elicit a 'similar' transcriptional response then they could share a therapeutic application) or by measuring the extent of 'anti-similarity' between drug-and disease-signature (i.e., if a drug is able to revert a phenotype signature then it could be able to 'revert the phenotype' as well). A review on this topic has been compiled by Iorio et al. 22 Such an approach has been performed by Kunkel et al. to develop a potential therapy for skeletal muscle atrophy. 23 Two sets of differentially expressed genes have been derived from the analysis of transcriptomics data taken from human and mouse muscle un- . Figure 4 . Genes distinguishing ALL from AML. The 50 genes most predictive in the ALL-AML class distinction are shown. Each row corresponds to a gene, with the columns corresponding to expression levels in different samples. The top panel shows genes highly expressed in ALL, the bottom panel shows genes more highly expressed in AML (Fig. taken from 12 ).
der spinal cord injury and fasting conditions. The authors then used these two gene-lists to search the connectivity map (CMAP) database. CMAP is a large collection of gene expression data following treatment by drugs and tool compounds. 24 The query system returned ursolic acid-a component of apple peal-with a gene expression list opposite of those of the disease condition (see Fig. 6 ). It was then experimentally verified that ursolic acid reduced muscle atrophy and stimulated muscle hypertrophy in mice. Moreover, they observed additional effects on the characteristics of muscle following treatment with ursolic acid, including reductions in adiposity, fasting blood glucose, plasma cholesterol and triglycerides. These findings suggest a potential use in muscle atrophy and other metabolic myopathies. Network inference. Not always signalling pathways or regulatory networks are sufficiently known to allow for a meaningful gene-set enrichment analysis or mapping of regulated genes onto pathway maps. In this case, regulators or regulatory networks have to be derived from the primary 'omics' data. Network reconstruction can be achieved, for example, by identifying correlations in expressed genes, using a number of methods including those based on information theory, Bayesian models and regression models. 18 In an attempt to identify additional type-2 diabetes (T2D) genes, Taneera et al. recently analyzed the gene expression in human islets using a systems genetics approach. 25 Human islets have been characterized from healthy and T2D patients by performing cDNA microarray and GWAS in addition to functional characterization (insulin response to glucose and glycemic control by HbA1c) from the same individuals. Using 48 genes located near T2D risk variants, the authors identified gene co-expression and proteinprotein interaction networks that were strongly associated with islet insulin secretion and HbA1c. The network data was integrated to form a list of putative T2D genes based on diverse criteria from different subanalyses. The resulting list of potential T2D genes highlights several candidate genes that might affect islet function. The study thus sheds some light into mechanisms impairing islet function and increasing the risk for T2D. In addition, several known, e.g. GLP1R and KCNJ11 (Kir6.2 channel), but also promising novel targets for a therapeutic treatment of T2D have been identified (e.g., GPR120). Counterparts to the top-down approaches are the bottom-up methodologies. Here, the modeler starts with individual components with well described properties and assembles them into a network with the goal to then describe or simulate the dynamic properties of the resulting system.
Depending on the detail and wealth of information available different routes can be taken. If the information on the components is rich (i.e., all interaction partners are known in molecular detail and all interactions and their kinetic parameters are available) molecular mechanistic models can be built. These will be discussed in the next section. If the knowledge about the kinetics in the system is sparse a number of other methodologies is available as will be exemplified in the section on logic-based models. In cases where molecular details are not known or of lower interest the dynamics of general physiological parameters (e.g., blood glucose levels, insulin secretion from the pancreas) can be modeled. This will be covered in the section on physiological models.
Molecular mechanistic models. In contrast to the network-based approaches that help to gain deeper understanding of huge amounts of data (e.g., 'omics' data) molecular mechanistic models are designed to paint a predictive and dynamic picture of a biological system of a smaller scale (e.g., a single signaling or metabolic pathway, Fig. 7) . Therefore, each reaction in the network is represented by a rate equation (ordinary differential equation = ODE) for which all rate constants need to be known or estimated. If a reaction follows a first order mass action mechanism only one rate constant constant is required. However, some biochemical reactions have a rather complex mechanism and the number of kinetic Figure 5 . Stratification of diseased training set patients and healthy controls by their levels of TNF signaling pathway strength. Patients that respond to infliximab are shown in green, non-responders in black, and healthy controls in grey. Patients with lower levels of TNF pathway activation were more likely to respond to infliximab (Fig. modified  from 13 ). Figure 6 . Identification of ursolic acid by matching of mRNA expression signatures. To develop a potential therapy for skeletal muscle atrophy the two unbiased mRNA expression signatures of muscle atrophy-resulting from fasting and spinal cord injury-have been used to query the Connectivity Map, which singled out ursolic acid as a compound whose signature was opposite to those of atrophy-inducing stresses. A natural compound enriched in apples, ursolic acid reduced muscle atrophy and stimulated muscle hypertrophy in mice (Fig. taken from 23 ). In addition to these parameters also the concentrations of all components (e.g., metabolites, receptors, enzymes) in the initial state of the system need to be known or estimated as starting point of the simulation. In any case, these parameters (kinetic parameters, concentrations of components) have to be fitted to the experimental time-course data of the specific cellular or physiological system that is analyzed. Such a detailed molecular-mechanistic model can then be used to simulate the dynamic behavior of the system. This is done by employing well established numerical ODE solvers which are part of modeling-software. The power of ODE based models is that they quantitatively predict the time course for each component in the system over the simulation period. Even for those components for which experimental data is not readily or only sparsely available (e.g., intermediate metabolites or second messengers), estimations for their quantitative and dynamic behavior can be derived from such a simulation.
The increasing number of published molecular-mechanistic models requires the setup of on-line repositories for these data. Over the last years several projects have established platforms that allow browsing and retrieving ODE based models, usually in standardized file formats (e.g., SBML or CellML). Well known repositories are, for example, BioModels, 29 CellML, 30 JWS Online, 31 VCell 32 and ModelDB. 33 Molecular mechanistic models have a comparatively long tradition in biological research. For example, already in 1952 Hodgkin and Huxley published the ground-breaking simulations of the membrane potential of the squid giant nerve axon. 34 This type of electrophysiological modeling inspired the modeling of the processes in cardiac cells that are responsible for the rhythmic contraction of the heart. A review by Noble et al. lists more than 100 heart cell models published between 1962 and 2011. 3 Such models are of high interest in pharmaceutical research for prediction of cardiac safety since they allow simulating desired and unwanted drug effects on the action potential of the cardiomyocyte. A prominent example is a potential drug side effect of the elongation of the QT interval in the electrocardiogram that can lead to lifethreatening arrhythmias. Since the block of the hERG potassium channel (KCNH2) can cause this QT elongation the 50% inhibitory concentration (IC 50 ) of a drug candidate on the hERG channel is often used as a marker for the risk of arrhythmias. Since hERG is not the only ion channel whose modification can change the QT interval the predictive power of the hERG IC 50 is only limited. Mirams et al. showed that mathematical models in conjunction with data on additional ion channels can provide much better predictors for the risk of arrhythmias than the IC 50 of hERG alone (Fig. 8) . 35 This example highlights how mathematical models can help to improve cardiac safety in drug discovery. Molecular mechanistic models can be applied for identification and/or validation of novel drug target by simulating the expected effect of a pharmacological intervention on a cellular system. The effect of drugs may be described by adding a drug binding event to its particular target to the model or by simply changing the value of those parameters that represent the biological activity of the drug target. For example, the activation of a receptor can be simulated by increasing the value of the parameter(s) that determine the activity of the receptor. The inhibition of an enzyme is expressed through the decrease of the rate constant of the corresponding enzyme. But not only the effects of existing drugs can be investigated, it is also possible to design 'virtual' drugs with completely new properties (new target, new binding properties to a receptor etc.) and to test the effect on a system readout of interest (e.g., amount of second messenger or cell cycle progression). These results then can help to design the blueprint for the desired drug profile that can guide drug discovery.
At Sanofi, aiming for the discovery of novel targets increasing the glucose-dependent insulin secretion, we have established a mathematical model of the pancreatic beta cell. The 'virtual pancreatic beta-cell' has been generated by capturing all relevant processes in this cell type by combining three published models describing elements in the control of glucose-triggered insulin secretion in the beta-cell (GPCR/cAMP signaling, b-cell electrophysiology and calcium handling, insulin granule exocytosis). 36 The resulting model contains numerous enzymes, transporters and ion-channels involved in glucose stimulated insulin secretion. Figure 9 shows an example of a simulation reflecting the predicted insulin secretion after stimulation by two important insulin secretagogues, the sulfonylurea Glimiperide and the incretin GLP1. Sulfonylureas (like Glimiperide) are an important class of oral drugs in the treatment of early diabetes since they increase insulin secretion after a meal. They act by closing an ATP sensitive potassium channel (K-ATP channel) and this effect can be simulated by Figure 7 . Mechanistic models attempt to copy nature by generating computational representations of biological processes (e.g., a molecular pathway or a physiological system). They translate a pictorial representation into mathematical equations. These can be used for the computational simulation of the time courses of all elements in the system following a perturbation (e.g., drug treatment).
decreasing the conductance of the K-ATP component in the model. An important but unwanted side effect of sulfonylureas is that they trigger insulin secretion at low glucose levels (i.e., under fasting conditions). This can result in severe hypoglycemia (below normal glucose levels). As shown in the left panel in Figure 9 this effect is also seen in the simulation. On the other hand, GLP1 only enhances insulin secretion at high glucose levels, thereby avoiding the risk of hypoglycemia. Therefore, GLP1-receptor agonists should have a better safety profile in diabetes treatment. The simulation of the GLP1 effect on the insulin secretion rate is shown in the right panel in Figure 9 . It correctly captures the improvement of the glucosedependent insulin secretion in presence of the GLP1 agonist. The 'virtual pancreatic b-cell' is currently used to predict the best drug targets or target combinations for increasing the glucose-dependent insulin secretion. Therefore, a sensitivity analysis is performed to identify the most sensitive 'screws' in the system connected to an improvement in insulin secretion.
Receptor tyrosine kinases are a family of receptors that attract high interest in drug development. Since this class includes a number of growth factor receptors that play a role in the development of cancer mathematical models of the downstream signaling pathways are highly relevant in the field of oncology.
An elaborate model of epidermal growth factor receptor (EGFreceptor) signaling had been designed by Chen, Schoeberl, Jasper and co-workers to investigate the importance of the four members of the EGF-receptor family (ErbB1-4) . 37 Since these members of the EGF-receptor family form homo-and heterodimers (each having individual properties) combinatorial complexity is added to the system. A version of this model that focused on the activation of AKT-also known as protein kinase B (PKB)-was then used to identify the member of the EGF-receptor family that was the most effective target for drug development. 39 Until then the development of therapeutic agents had focused on the receptor forms ErbB1 and ErbB2. However, a sensitivity analysis performed with this model could show that AKT activation was most sensitive to an intervention at the ErbB3 form of the receptor family. This led to the development of the ErbB3 specific antibody MM-121 that is active in cancers with ligand-dependent receptor activation. 38, 39 This drug is now in clinical development.
Logic-based models. ODE based models require the complete knowledge of the parameters used in the system, but often this is incomplete and no reliable estimates can be made for the unknown variables. However, even pathways or networks for which no kinetic parameters are known can be used for valuable systems analysis. In many cases the literature provides qualitative or halfquantitative statements on an interaction between biological components (e.g., receptor A activates kinase B-but time course and quantity of the activation are unknown). Such data can be handled, for example, in logic-based modeling approaches. 40 A common type of logic applied here is the Boolean logic. For each node (component) in the network only two states are possible (e.g., 'on' or 'off') and the vertices (interactions) are causal relationships (e.g., 'if A is on then B is off'). Since nodes can have more than one input logical rules are put in place to ensure that for each input combina- Figure 8 . Simulation of the changes in action potential duration under increasing concentrations of verapamil. In the left panel only the effect of a hERG block was considered while the right panel shows the effect of verapamil when considering a hERG, Na and CaL block. The arrows indicate the effect on the action potential of increasing drug concentration. This simulation shows that the effect of a hERG block on the action potential viewed in isolation can be misleading. Also the effects on other ion channels need to be considered ( Fig. from Mirams et al. 35 ). Figure 9 . Simulation of the effect of Glimiperide and GLP1 on insulin secretion in the 'virtual pancreatic b-cell'. 36 Simulated were experiments of the perfused isolated rat pancreas where a drug was applied at 3 min and the glucose concentration in the perfusate was increased from 5.6 to 16.7 mM at 12 min. The effect of Glimiperide was modeled by reducing the conductance of the K-ATP channel by 75%, the effect of GLP1 by increasing the activity of the GLP1-receptor. In agreement with experimental data, Glimiperide directly triggers insulin secretion even at low glucose levels, whereas GLP1 only acts at high glucose-levels by improving glucose-dependent insulin secretion.
tion a decision for the node is taken (e.g., an AND-gate: 'if A is on AND B is on then C is on'). An input (e.g., receptors A and C are set to 'on') into such a Boolean network can then be propagated in discrete time steps. Mutations or inhibition of components can be modeled by removing the corresponding node or vertex from the network. The methodology and biological applications are discussed, for example, in the reviews by Bornholdt or Morris and coworkers. 40, 41 An example of Boolean network modeling has recently been presented by Saez-Rodriguez et al. 42 This group used a literature based Boolean prior knowledge network of immediate-early signaling in liver cells and trained it on biochemical data obtained from hepatocytes and four hepatic cancer cell lines under various treatments. The models generated by the fit differed between the cell types by the absence or presence of edges. Therefore, this study uncovered differences in the wiring of the growth factor signaling network between normal hepatocytes and transformed cells. Such knowledge can be an important contribution to understanding these types of cancer and to develop a suitable and effective therapy. In addition the study was able to identify an off-target effect of an IKK inhibitor on Jak2, based on the discrepancy between the model and the phosphoproteomics data. Physiological models. Biological systems need not always be presented on the level of molecular detail. A different approach is taken by physiological models. Like molecular mechanistic models they are ODE based and can present the dynamics of a system. But instead of focusing on individual enzymes, receptors etc. they try to model a physiological aspect of a whole organism. For example, this can be the secretion of insulin from the pancreas or the uptake of glucose from the blood stream into peripheral tissues.
One class of physiological models, the so-called 'minimal models', is designed to describe the measurements of a specific type of physiological or clinical experiment and connect these data to a small set of physiological parameters of interest. 43 Usually, these models are not intended to run forward simulations to predict measurements but they are used in the opposite (diagnostic) way: using mathematical optimization algorithms the model is fitted to measured data in order to determine the values of the models parameter set. An example for this is the application of mathematical models in the oral glucose tolerance test (OGTT). In this test a patient ingests a defined amount of glucose. Afterwards, the time course of blood glucose and insulin levels is measured. Minimal models now can be fitted to these time courses to yield indices for the ability of the pancreas to release insulin upon a glucose stimulus ('beta-cell responsivity') and the ability of peripheral tissues to remove glucose from the blood stream upon an insulin stimulus ('insulin sensitivity'). 44 In order to produce robust and precise parameter estimates minimal models need to contain only a small number of parameters and components. If the design of the model is too complex determination of parameters by the optimization algorithm can become problematic (the parameters are 'non-identifiable'). Consequently, minimal models can be seen rather as diagnostic than predictive tools. In our example the minimal models can help to investigate if a diabetic patient has decreased beta-cell responsivity or decreased insulin sensitivity.
Minimal models can also be applied to long-term disease progression. An example is the mechanism-based disease progression model by de Winter et al. 45 The model describes the progressive loss of b-cell function and insulin sensitivity in Type 2 Diabetes Mellitus. By fitting this model to the data of the treatment arms of a 52 week clinical study it was able to describe the different effect of three drugs on the model parameters affecting disease progression. But of course, the model can also be used for forward simulation of disease progression, for example, to check what effects an improvement of insulin sensitivity has compared to an improvement of b-cell function on the clinical endpoint. The so-called 'maximal models' are comprehensive descriptions attempting to fully implement the body of information available for a system. Because of the comparatively high number of parameters these models are usually not completely identifiable. As a consequence, parameter values need to be drawn from various different experimental sources or through expensive and complex experimental approaches from single patients. As a result the maximal model often represents an 'average patient/system' and is used for systems simulation.
To give an example, in 2008 such a mathematical model of type 1 diabetes was accepted by the FDA as a substitute for preclinical animal trials in artificial pancreas studies. 46, 47 The model captures the glucose-insulin system and describes all major physiological processes involved in plasma glucose homeostasis (glucose stimulated insulin secretion in the pancreas, insulin stimulated glucose uptake in peripheral tissues, glucose absorption from the intestines, glucose production in the liver etc.). 48 A layout of the model is shown in Figure 10 . The parameters of this model have been obtained not only by following the serum insulin and plasma glucose dynamics but also by extensive validation against various glucose fluxes obtained from 204 normal individuals who underwent a tri- ple tracer meal protocol. An equivalent parameter set has been obtained for type 2 diabetic individuals. The simulator allows the scientist to follow glucose and insulin levels during the course of a day with varying meal schedules. Also the effects of a virtual drug (e.g., a drug that improves insulin secretion in a diabetic individual) can be simulated. This can be done by changing those parameters in the model that are hypothesized to be affected by the drug of interest. For an anti-diabetic drug in the glucose-insulin model this could for, example, be the parameters that describe insulin sensitivity or insulin secretion. Thus, this type of mathematical model can help to find those drug profiles that are most promising in treating a disease effectively. In addition, they can be used to predict the clinical efficacy of drugs in virtual patients and to select the most-promising drug candidate. Obviously, physiological models have a great potential in the design and support of clinical trials. For example, they can help to narrow the dose range that needs to be tested or to devise the best time points to take clinical measurements. To aid drug development several commercial companies now offer physiological models and services in this area (e.g., Bayer Technology Services, Entelos and Rosa & Co). [49] [50] [51] So far, we have discussed molecular mechanistic models and physiological models separately. However, in drug discovery and pharmacology it can be useful to merge these approaches. In a recent article Iyengar et al. outlined this strategy that they named enhanced pharmacodynamic (ePD) model. 52 As an illustration they presented an example from oncology: a mechanistic description of the EGFR signaling pathway was combined with a more physiological description on the effect of certain cell cycle factors on proliferation and tumor growth. Since the mechanistic part in this model could describe genomic and epigenetic alterations in individual patients the authors could predict the patient response on the level of tumor growth to a treatment with an anticancer drug. This example points out how ePD models could generate impact in personalized medicine.
In conclusion, over the last years we have seen a paradigm shift in how we view biology. Instead of focusing on isolated components we now turn our attention to the properties of a biological system as a whole. In this holistic view a certain biological property is not necessarily caused by a single gene or protein but by the sometimes complex interplay of components in a network. Of course, this 'systems view' has also an impact on drug development. Drug candidates discovered-following the traditional target-centric approach-often failed in clinical trials, as the observed drug potency in in vitro assay systems or animal models often did not translate in sufficient efficacy in humans. Expectations are high that a systems approach will lead to a more successful discovery of novel therapies. Technical advances, especially the advent of 'omics' technologies and the increased capabilities of computers, have made it possible to investigate biological systems under the new paradigm. This digest reflects the current state of the systems biology field with respect to the impact in drug development. A number of examples show that systems approaches can be successful in various areas like target identification, patient stratification, drug repurposing, simulation of drug effects and clinical trial design. Even though systems biology is an evolving discipline and is only starting to show its impact it obviously has a huge potential. Systems approaches are already increasingly employed to answer biological questions. However, so far the high expectations have only been met in part and more years of research will be required to unleash the full potential of systems biology.
